This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.
Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.
Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down
by Zacks Equity Research
Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.
Ecolab (ECL) Earnings and Revenues Match Estimates in Q4
by Zacks Equity Research
Ecolab (ECL) sees solid segmental gains in Q4.
Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
by Zacks Equity Research
Cryolife (CRY) revenues increase year over year across all geographies and major segments.
Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
by Zacks Equity Research
In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
Bio-Techne (TECH) sees increase in revenues across key segments.
DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates
by Zacks Equity Research
DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.
Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental performance in Q4.
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
by Zacks Equity Research
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q3.
IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
IRADIMED (IRMD) reports growth across all operating segments and geographies
Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.
Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View
by Zacks Equity Research
Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.
Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3
by Zacks Equity Research
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip
by Zacks Equity Research
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.
Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.
Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster
by Zacks Equity Research
Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
by Zacks Equity Research
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates
by Zacks Equity Research
Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.
Omnicell Solid on Geographic Expansion Amid Stiff Competition
by Zacks Equity Research
Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.